Sector
PharmaceuticalsOpen
₹4.1Prev. Close
₹4.15Turnover(Lac.)
₹14.14Day's High
₹4.3Day's Low
₹3.9552 Week's High
₹052 Week's Low
₹0Book Value
₹10Face Value
₹10Mkt Cap (₹ Cr.)
17P/E
0EPS
0Divi. Yield
0No Record Found
Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|
Equity Capital | 3.55 | 3.55 | 40 | 40 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 0 | 0 | -57.32 | -52.42 |
Net Worth | 3.55 | 3.55 | -17.32 | -12.42 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 1.83 | 19.96 | 41.53 | 52.83 |
yoy growth (%) | -90.82 | -51.92 | -21.4 | -16.02 |
Raw materials | -2.57 | -12.77 | -24.19 | -35.73 |
As % of sales | 140.47 | 63.99 | 58.26 | 67.62 |
Employee costs | -1.67 | -5.15 | -10.66 | -9.22 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | -4.93 | -4.14 | -8.79 | -7.71 |
Depreciation | -1.99 | -2.29 | -3.73 | -4.6 |
Tax paid | 0 | 0 | 0 | -7.9 |
Working capital | -2.05 | -18.82 | -18.57 | -22.8 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -90.82 | -51.92 | -21.4 | -16.02 |
Op profit growth | 80.81 | -64.58 | 125.44 | -461.18 |
EBIT growth | 27.24 | -54.65 | 84.32 | 352.73 |
Net profit growth | -58.1 | -82.11 | -15.79 | 2,102.81 |
Particulars (Rupees in Crores.) | Mar-2018 | Mar-2017 | Mar-2016 | Mar-2015 | Mar-2014 |
---|---|---|---|---|---|
Gross Sales | 41.85 | 55.67 | 122.89 | 189.86 | 191.58 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 41.85 | 55.67 | 122.89 | 189.86 | 191.58 |
Other Operating Income | 0 | 0 | 1.01 | 1.31 | 0 |
Other Income | 0.39 | 2.25 | 2.98 | 2.77 | 3.06 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,827.45 | 156.94 | 4,32,660.08 | 863.29 | 0.75 | 5,123.67 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,954.15 | 92.83 | 1,54,189.46 | 430 | 0.52 | 2,063 | 507.93 |
Cipla Ltd CIPLA | 1,594.05 | 30.54 | 1,29,316.22 | 1,178.16 | 0.81 | 3,969.86 | 360.74 |
Mankind Pharma Ltd MANKIND | 2,748.85 | 58.01 | 1,08,750.85 | 634.43 | 0 | 2,529.74 | 240.2 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,209.9 | 65.92 | 1,07,835.72 | 460 | 0.88 | 2,376 | 222.38 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Independent Director
Sunita Garg
Independent Director
Tushar Patodia
Managing Director
Ajay Shankarlal Bankda
Director
Manoj Negi
Independent Director
Bhishampal Singh Yadav
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Syncom Healthcare Ltd
Summary
Syncom Healthcare Ltd is engaged in the manufacture, marketing and trade of pharmaceutical formulations. The company manufactures a range of products such as Ethical drugs, Generic drugs, over the counter drugs (OTC) and Herbal formulations in various dosage forms and markets them under the trade mark, Syncom.The company also undertakes contract manufacturing for large variety of pharmaceutical formulations for a number of other pharmaceutical companies of national and international repute such as Lupin Ltd, Nicholas Piramal India Ltd, Galpha Laboratories Ltd, Percos India Pvt Ltd etc (under their own brands) located in India.The company manufactures various dosage forms, which include tablets, capsules, eye/ ear drops, ointment and creams and dry syrups. They have an established product-marketing network covering both metro and mini-metro cities, which enable them to reach their existing and potential customers through their network of distributors and dealers spread across the country. Syncom Healthcare Ltd was incorporated on July 29, 2002 for marketing of pharmaceutical formulations. The company was promoted by Ajay S Bankda and Jyoti Bankda. The company received the certificate for commencement of business on August 2, 2002. Initially, the company started their journey with the marketing of the pharmaceuticals products manufactured by others under their own brand. In May 10, 2004, the company entered into a Deed of Assignment of Trade Marks with Syncom Formulations (Indi
Read More
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice